Navigation Links
Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
Date:3/24/2009

ANTONY, France, March 24 /PRNewswire-FirstCall/ -- Stallergenes S.A. and Solvay Pharmaceuticals Marketing and Licensing AG (subsidiary of Solvay Group) announce the signing of an exclusive partnership agreement for the promotion and distribution of Stallergenes diagnostic and treatment products in Russia and the Commonwealth of Independent States (CIS).

With an estimated 20 million allergy sufferers and a strong demand on the part of the medical community for quality products, the Russian market represents a real opportunity for Stallergenes.

The main products in Stallergenes' injectable and sublingual ranges will soon be the subject of registration applications. This partnership will enable Stallergenes to meet more than 80% of the needs of allergy sufferers in Russia and the CIS by 2011.

"We're delighted to be teaming up with Solvay Pharmaceuticals to target the potential growth this new market represents. Thanks to its franchise and its considerable expertise recognized by allergy specialists, Solvay Pharmaceuticals will enable us to promote the desensitization standardized products, and notably the sublingual route, and their benefits for patients," declared Albert Saporta, Stallergenes' Chairman and CEO.

"We're tremendously enthusiastic about the prospect of collaborating with the world leader in sublingual desensitization therapy and making its innovative standardized products available to practitioners," emphasizes Mr. Jens Neuschaefer, Vice President, Regional Director, Solvay Pharmaceuticals.

*countries concerned: Russia, Georgia, CIS (Commonwealth of Independent States: Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldavia, Uzbekistan, Russia, Tajikistan, Turkmenistan, and Ukraine).

About Stallergenes' International Development

Today, Stallergenes markets its products in more than 50 different countries, via 11 subsidiaries throughout Europe and numerous distribution and partnership agreements around the globe.

To help it pursue its development in new markets, Stallergenes is supported by unique expertise and the responsiveness of its structure. In high-potential emerging markets such as Russia, Stallergenes adopts a tailored product offer strategy, working with partners closely involved in the field of respiratory allergy treatment.

In the last five years, five new subsidiaries have been opened in Europe and several partnership agreements have been signed.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, such as rhinoconjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 21% of its turnover, in gross terms, to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.

In 2008, Stallergenes had a turnover of 171 million euros and more than 500,000 patients were treated with Stallergenes desensitization products.

Stallergenes is listed on Euronext Paris (Compartment B and is part of the sample composing the SBF 120 index.

    ISIN code: FR0000065674
    Reuters code: GEN.PA
    Bloomberg code: GEN.FP
    Additional information is available athttp://www.stallergenes.com
    About Solvay Pharmaceuticals

Solvay Pharmaceuticals is a research driven group of companies that constitutes the global pharmaceutical business of the Solvay Group. These companies seek to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology and men's and women's health. Its 2008 sales were EUR 2.7 billion, and it employs more than 9,000 people worldwide. For more information, visit http://www.solvaypharmaceuticals.com.

SOLVAY GROUP is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs more than 29,000 people in 50 countries. In 2008, its consolidated sales amounted to EUR 9.5 billion, generated by its three sectors of activity: Chemicals, Plastics and Pharmaceuticals. Solvay is listed on the NYSE Euronext stock exchange in Brussels (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR). Details are available at http://www.solvay.com.


'/>"/>
SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
2. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
3. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
4. Stallergenes Inaugurates the Biggest Pharmaceutical Allergen Production Unit in the World
5. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
6. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
7. Stallergenes : Sublingual Desensitisation Tablets Oralair Grasses Approved in Germany
8. STALLERGENES : Further Profit Growth Acceleration of R&D Expenditure
9. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
10. STALLERGENES and Protein eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens
11. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission ... hardware projects are designed, built and brought to market. , The Design Lab ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... focused on quality, regulatory and technical consulting, provides a free webinar ... presented on July 13, 2016 at 12pm CT at no charge. , Incomplete ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
Breaking Biology News(10 mins):